| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
33,580,000 |
| Market
Cap: |
135.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.738 - $4.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 11.3 |
| Insider 6 Months : 13.5 |
| Insider 3/6 Months : 24.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases related to chronic glucose imbalance. Co.'s primary clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism, a pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Co.'s second clinical asset, RZ402, is an oral plasma kallikrein inhibitor being developed as a potential therapy for the chronic treatment of diabetic macular edema.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
128,954 |
199,854 |
204,854 |
3,441,696 |
| Total Buy Value |
$253,344 |
$351,167 |
$360,667 |
$12,660,667 |
| Total People Bought |
3 |
4 |
4 |
5 |
| Total Buy Transactions |
11 |
17 |
18 |
20 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-05 |
2023-12-03 |
2023-06-04 |
2022-06-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Evans Daron |
CFO |
• • – |
2024-05-29 |
4 |
B |
$3.50 |
$1,579 |
D/D |
451 |
121,351 |
0.01 |
- |
|
| Evans Daron |
CFO |
• • – |
2024-05-24 |
4 |
B |
$3.23 |
$9,503 |
I/I |
2,942 |
13,000 |
0.01 |
17% |
|
| Evans Daron |
CFO |
• • – |
2024-05-23 |
4 |
B |
$2.85 |
$165 |
I/I |
58 |
10,058 |
0.01 |
36% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-05-23 |
4 |
B |
$2.68 |
$20,138 |
D/D |
7,500 |
50,052 |
0.01 |
36% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-03-28 |
4 |
B |
$2.55 |
$1,275 |
I/I |
500 |
1,076 |
0.01 |
63% |
|
| Evans Daron |
CFO |
• • – |
2024-03-15 |
4 |
B |
$1.69 |
$33,830 |
I/I |
20,000 |
20,000 |
0.01 |
133% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-03-14 |
4 |
B |
$1.88 |
$18,800 |
I/I |
10,000 |
10,000 |
0.01 |
128% |
|
| Evans Daron |
CFO |
• • – |
2024-03-08 |
4 |
B |
$1.93 |
$96,345 |
D/D |
50,000 |
120,900 |
0.01 |
118% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-03-07 |
4/A |
B |
$1.85 |
$925 |
I/I |
500 |
576 |
0.01 |
- |
|
| Kim Young-Jin |
|
• • – |
2024-03-07 |
4 |
B |
$1.91 |
$69,859 |
D/D |
36,503 |
115,450 |
0.01 |
129% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-03-07 |
4 |
B |
$1.85 |
$925 |
I/I |
500 |
500 |
0.01 |
129% |
|
| Elam Nevan C |
CEO |
• • – |
2024-02-26 |
4 |
B |
$1.68 |
$8,400 |
D/D |
5,000 |
7,817 |
0.01 |
153% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-02-26 |
4 |
B |
$1.70 |
$3,400 |
D/D |
2,000 |
42,552 |
0.01 |
153% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-02-23 |
4 |
B |
$1.69 |
$10,140 |
D/D |
6,000 |
40,552 |
0.01 |
141% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2024-02-16 |
4 |
B |
$1.31 |
$9,142 |
D/D |
7,000 |
34,552 |
0.01 |
207% |
|
| Evans Daron |
CFO |
• • – |
2024-02-16 |
4 |
B |
$1.37 |
$12,330 |
I/I |
9,000 |
4,500 |
0.01 |
207% |
|
| Evans Daron |
CFO |
• • – |
2024-02-16 |
4 |
B |
$1.30 |
$54,411 |
D/D |
41,900 |
70,900 |
0.01 |
207% |
|
| Evans Daron |
CFO |
• – – |
2024-01-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,000 |
|
323% |
|
| Evans Daron |
CFO |
• – – |
2024-01-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,000 |
|
323% |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2023-07-03 |
4 |
B |
$1.90 |
$9,500 |
D/D |
5,000 |
27,552 |
0.01 |
-51% |
|
| Handok, Inc. |
|
• • • |
2022-07-22 |
4 |
B |
$3.80 |
$12,000,001 |
D/D |
3,157,895 |
5,942,617 |
0.01 |
-42% |
|
| Kim Young-Jin |
|
• • – |
2022-07-22 |
4 |
B |
$3.80 |
$299,999 |
D/D |
78,947 |
78,947 |
0.01 |
-42% |
|
| Roberts Brian Kenneth |
Sr VP, Clinic Development |
• – – |
2022-05-19 |
4 |
B |
$2.95 |
$884 |
D/D |
300 |
22,552 |
2.66 |
-10% |
|
| Roberts Brian Kenneth |
Sr VP, Clinic Development |
• – – |
2022-05-18 |
4 |
B |
$2.86 |
$572 |
D/D |
200 |
22,252 |
2.66 |
-2% |
|
| Roberts Brian Kenneth |
Sr VP, Clinic Development |
• – – |
2022-05-17 |
4 |
B |
$3.41 |
$3,407 |
D/D |
1,000 |
22,052 |
2.66 |
-25% |
|
142 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (2.89%) 
